Roche makes a plat­form play, bet­ting $190M in cash on Ar­rakis’ long-haul plans to drug RNA

Every biotech start­up sets out at its own idea of a de­lib­er­ate pace. And they of­ten fall in­to 2 sep­a­rate styles.

There are the sprint­ers who leap straight in­to a slate of deals, look­ing to align them­selves with the kind of blue chip part­ners that help val­i­date their place in the de­vel­op­ment pipeline.

And then there are the marathon, long-haul biotechs like Ar­rakis, which take a more mea­sured ap­proach.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER